Denosumab (Xgeva)

  • Part D specialty tier in 92% of formularies (2026Q3)
  • Biologic
  • XGEVA

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Denosumab (Xgeva): storage and handling

Freezing
Do not freeze
Label statement
Do not freeze.
Room temperature
at or below 25°C (77°F)
Label statement
Prior to administration, Xgeva may be allowed to reach room temperature up to 25°C (77°F) in the original container.
Room temperature
up to 30 days at or below 25°C (77°F)
Label statement
Once removed from the refrigerator, Xgeva must not be exposed to temperatures above 25°C (77°F) and must be used within 30 days.
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Do not shake
Label statement
Avoid vigorous shaking of Xgeva.

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

Within the label's stated room-temperature allowance (at up to 25°C (77°F)). Follow the label's instructions for what to do next.

Entered: 1 day at up to 77°F (25°C).

Prior to administration, Xgeva may be allowed to reach room temperature up to 25°C (77°F) in the original container.
Discard Xgeva if not used within the 30 days.

If anything else happened to the product, or you are unsure, Contact the manufacturer about this product; the label text ClinDose has does not print a phone number for it.

All storage statements on the label (6)
  • Do not freeze.
  • Prior to administration, Xgeva may be allowed to reach room temperature up to 25°C (77°F) in the original container.
  • Once removed from the refrigerator, Xgeva must not be exposed to temperatures above 25°C (77°F) and must be used within 30 days.
  • Discard Xgeva if not used within the 30 days.
  • Protect Xgeva from direct light and heat.
  • Avoid vigorous shaking of Xgeva.

FDA label version 177, effective June 23, 2026. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Biosimilars

Xgeva: 20 licensed biosimilar products, 20 interchangeable (FDA Purple Book). Compare presentations and dates

Medicare Part D coverage

32%of plans list it
100%of those: prior authorization
0%step therapy
85%quantity limit
99%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.